Robert A Feldman1, Rainard Fuhr2, Igor Smolenov3, Amilcar Mick Ribeiro3, Lori Panther4, Mike Watson5, Joseph J Senn6, Mike Smith7, Ӧrn Almarsson8, Hari S Pujar9, Michael E Laska3, James Thompson10, Tal Zaks11, Giuseppe Ciaramella3. 1. Miami Research Associates, 6280 Sunset Drive, Suite 600, So. Miami, FL 33143, USA. 2. PAREXEL International GmbH Klinikum Westend, House 18, Spandauer Damm 130, 14050 Berlin, Germany. Electronic address: Rainard.Fuhr@parexel.com. 3. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. 4. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. Electronic address: Lori.Panther@modernatx.com. 5. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. Electronic address: mike.watson@modernatx.com. 6. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. Electronic address: Joe.senn@modernatx.com. 7. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. Electronic address: Mike.smith@modernatx.com. 8. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. Electronic address: Orn.almarsson@modernatx.com. 9. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. Electronic address: Hari.pujar@modernatx.com. 10. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. Electronic address: James.thompson@modernatx.com. 11. Moderna, 500 Technology Square, Cambridge, MA 02139, USA. Electronic address: Tal.zaks@modernatx.com.
Abstract
BACKGROUND: We evaluated safety and immunogenicity of the first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses. METHODS: Two randomized, placebo-controlled, double-blind, phase 1 clinical trials enrolled participants between December 2015 and August 2017 at single centers in Germany (H10N8) and USA (H7N9). Healthy adults (ages 18-64 years for H10N8 study; 18-49 years for H7N9 study) participated. Participants received vaccine or placebo in a 2-dose vaccination series 3 weeks apart. H10N8 intramuscular (IM) dose levels of 25, 50, 75, 100, and 400 µg and intradermal dose levels of 25 and 50 µg were evaluated. H7N9 IM 10-, 25-, and 50-µg dose levels were evaluated; 2-dose series 6 months apart was also evaluated. Primary endpoints were safety (adverse events) and tolerability. Secondary immunogenicity outcomes included humoral (hemagglutination inhibition [HAI], microneutralization [MN] assays) and cell-mediated responses (ELISPOT assay). RESULTS:H10N8 and H7N9 mRNAIM vaccines demonstrated favorable safety and reactogenicity profiles. No vaccine-related serious adverse event was reported. For H10N8 (N = 201), 100-µg IM dose induced HAI titers ≥ 1:40 in 100% and MN titers ≥ 1:20 in 87.0% of participants. The 25-µg intradermal dose induced HAI titers > 1:40 in 64.7% of participants compared to 34.5% of participants receiving the IM dose. For H7N9 (N = 156), IM doses of 10, 25, and 50 µg achieved HAI titers ≥ 1:40 in 36.0%, 96.3%, and 89.7% of participants, respectively. MN titers ≥ 1:20 were achieved by 100% in the 10- and 25-µg groups and 96.6% in the 50-µg group. Seroconversion rates were 78.3% (HAI) and 87.0% (MN) for H10N8 (100 µg IM) and 96.3% (HAI) and 100% (MN) in H7N9 (50 µg). Significant cell-mediated responses were not detected in either study. CONCLUSIONS: The first mRNA vaccines against H10N8 and H7N9 influenza viruses were well tolerated and elicited robust humoral immune responses. ClinicalTrials.gov NCT03076385 and NCT03345043.
RCT Entities:
BACKGROUND: We evaluated safety and immunogenicity of the first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses. METHODS: Two randomized, placebo-controlled, double-blind, phase 1 clinical trials enrolled participants between December 2015 and August 2017 at single centers in Germany (H10N8) and USA (H7N9). Healthy adults (ages 18-64 years for H10N8 study; 18-49 years for H7N9 study) participated. Participants received vaccine or placebo in a 2-dose vaccination series 3 weeks apart. H10N8 intramuscular (IM) dose levels of 25, 50, 75, 100, and 400 µg and intradermal dose levels of 25 and 50 µg were evaluated. H7N9 IM 10-, 25-, and 50-µg dose levels were evaluated; 2-dose series 6 months apart was also evaluated. Primary endpoints were safety (adverse events) and tolerability. Secondary immunogenicity outcomes included humoral (hemagglutination inhibition [HAI], microneutralization [MN] assays) and cell-mediated responses (ELISPOT assay). RESULTS:H10N8 and H7N9 mRNA IM vaccines demonstrated favorable safety and reactogenicity profiles. No vaccine-related serious adverse event was reported. For H10N8 (N = 201), 100-µg IM dose induced HAI titers ≥ 1:40 in 100% and MN titers ≥ 1:20 in 87.0% of participants. The 25-µg intradermal dose induced HAI titers > 1:40 in 64.7% of participants compared to 34.5% of participants receiving the IM dose. For H7N9 (N = 156), IM doses of 10, 25, and 50 µg achieved HAI titers ≥ 1:40 in 36.0%, 96.3%, and 89.7% of participants, respectively. MN titers ≥ 1:20 were achieved by 100% in the 10- and 25-µg groups and 96.6% in the 50-µg group. Seroconversion rates were 78.3% (HAI) and 87.0% (MN) for H10N8 (100 µg IM) and 96.3% (HAI) and 100% (MN) in H7N9 (50 µg). Significant cell-mediated responses were not detected in either study. CONCLUSIONS: The first mRNA vaccines against H10N8 and H7N9 influenza viruses were well tolerated and elicited robust humoral immune responses. ClinicalTrials.gov NCT03076385 and NCT03345043.
Authors: Alec W Freyn; Jamile Ramos da Silva; Victoria C Rosado; Carly M Bliss; Matthew Pine; Barbara L Mui; Ying K Tam; Thomas D Madden; Luís Carlos de Souza Ferreira; Drew Weissman; Florian Krammer; Lynda Coughlan; Peter Palese; Norbert Pardi; Raffael Nachbagauer Journal: Mol Ther Date: 2020-04-19 Impact factor: 11.454
Authors: Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett Journal: NPJ Vaccines Date: 2020-02-14 Impact factor: 7.344
Authors: Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman Journal: Transl Res Date: 2020-03-16 Impact factor: 7.012
Authors: Chester E Markwalter; Robert F Pagels; Ava N Hejazi; Akiva G R Gordon; Alexandra L Thompson; Robert K Prud'homme Journal: AAPS J Date: 2020-01-02 Impact factor: 4.009
Authors: Elinor Willis; Norbert Pardi; Kaela Parkhouse; Barbara L Mui; Ying K Tam; Drew Weissman; Scott E Hensley Journal: Sci Transl Med Date: 2020-01-08 Impact factor: 17.956
Authors: Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther Journal: Hum Vaccin Immunother Date: 2020-10-29 Impact factor: 3.452